Princeton Bancorp vs Peoples Bancorp
BPRN and PEBO side by side, both in commercial banks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BPRN and PEBO compare
Peoples Bancorp is the larger company, worth 4.5 times as much as Princeton Bancorp ($1.4B against $300M).
On earnings, Peoples Bancorp is cheaper: it trades at 11.1× trailing earnings, against 11.6× for Princeton Bancorp.
Princeton Bancorp grew revenue faster over the last twelve months (6.0% versus 2.8% for Peoples Bancorp).
Peoples Bancorp keeps more of each dollar of sales as profit, with a net margin of 136% compared with 30.0% at Princeton Bancorp.
Both pay dividends: Princeton Bancorp yields 3.3% and Peoples Bancorp 4.4%.
Peoples Bancorp scores higher on the StockData Score (15 against 12 for Princeton Bancorp), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BPRN | PEBO |
|---|---|---|
| Size and price | ||
| Market cap | $300M | $1.4B |
| Share price | $43.99 | $37.70 |
| Change, 1 year | 31.6% | 29.7% |
| Change, 5 years | 45.5% | 20.2% |
| Beta (5Y) | 0.38 | 0.03 |
| Employees | 241 | 1,454 |
| StockData Score | ||
| Total score | 12 | 15 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 0 | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 4 | 5 (better) |
| Valuation | ||
| P/E | 11.6× | 11.1× (better) |
| P/S | 3.5× (better) | 15.2× |
| P/B | 1.1× (better) | 1.1× |
| EV/EBITDA | – | 11.5× |
| P/FCF | 12.8× | 7.9× (better) |
| FCF yield | 7.8% | 12.6% (better) |
| Fair value | $45.71 | $37.31 |
| Margin of safety | 3.8% (better) | −1.0% |
| Growth | ||
| Revenue growth (TTM) | 6.0% (better) | 2.8% |
| Revenue growth, 5Y average | – | 10.0% |
| Net income growth (TTM) | 278% (better) | 19.0% |
| EPS growth (TTM) | – | 18.5% |
| EPS growth, 5Y average | – | 11.6% |
| Profitability | ||
| Operating margin | – | 171% |
| Net margin | 30.0% | 136% (better) |
| FCF margin | 27.2% | 192% (better) |
| Return on equity | 9.5% | 10.1% (better) |
| Return on invested capital | – | 7.7% |
| Financial health | ||
| Debt / equity | – | 0.57 |
| Net debt / EBITDA | – | 2.65 |
| Altman Z-score | 0.24 (better) | 0.23 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 3.3% | 4.4% (better) |
| Payout ratio | 35.2% | 49.1% |
| Years of dividend growth | 1 | 8 (better) |
| Dividend growth, 5Y average | – | 3.5% |
| Buyback yield | 0.85% (better) | −0.07% |
| Shareholder yield | 4.1% | 4.4% (better) |
| Ownership | ||
| Held by institutions | 45.6% | 66.0% |
| Held by insiders | 21.4% | 3.8% |
| Insider net buying, 12 months | −$24.7K (better) | −$455K |
| Short interest, % of float | 0.99% | 8.4% |
Go deeper
- BPRN stock overview
- BPRN income statement
- BPRN valuation and score
- PEBO stock overview
- PEBO income statement
- PEBO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.